JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Building and Pilot Testing a Couples-based Smartphone Systems to Address Alcohol Use Disorder

  NCT04059549

  Conditions:   Alcohol Use Disorder;   Couples;   Behavior, Addictive
  Interventions:   Behavioral: PartnerCHESS;   Behavioral: A-CHESS
  Sponsors:   University of Wisconsin, Madison;   University of Massachusetts, Worcester;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  Recruiting
• Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings

  NCT03698669

  Condition:   Opioid-Related Disorders
  Interventions:   Behavioral: Treating Opioid Patients' Pain and Sadness (TOPPS);   Behavioral: Health Education (HE)
  Sponsors:   Boston University;   National Institute on Drug Abuse (NIDA)
  Recruiting
• Clinical Concordance Evaluation of T-SPOT®.TB Assay Performance (T-Cell SelectTM Study)

  NCT04141982

  Condition:   Tuberculosis
  Intervention:   Diagnostic Test: T-Cell SelectTM Kit
  Sponsor:   Oxford Immunotec
  Recruiting
• Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome

  NCT03951077

  Condition:   Polycystic Ovary Syndrome
  Interventions:   Drug: Elagolix;   Drug: Placebo
  Sponsor:   AbbVie
  Recruiting
• A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

  NCT03886220

  Condition:   Uterine Fibroids
  Interventions:   Drug: Elagolix;   Drug: Placebo
  Sponsor:   AbbVie
  Recruiting
• AMPLATZER PFO Occluder Post Approval Study

  NCT03309332

  Conditions:   Stroke;   Patent Foramen Ovale
  Intervention:   Device: AMPLATZER™ PFO Occluder
  Sponsor:   Abbott Medical Devices
  Recruiting
• A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease

  NCT03677648

  Condition:   Crohn's Disease
  Interventions:   Drug: SHR0302;   Drug: Placebos
  Sponsor:   Reistone Biopharma Company Limited
  Recruiting
• A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.

  NCT03675477

  Condition:   Ulcerative Colitis
  Interventions:   Drug: SHR0302;   Drug: Placebos
  Sponsor:   Reistone Biopharma Company Limited
  Recruiting
• A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

  NCT04184622

  Conditions:   Overweight;   Obesity
  Interventions:   Drug: Tirzepatide;   Drug: Placebo
  Sponsor:   Eli Lilly and Company
  Recruiting
• A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

  NCT03987919

  Condition:   Type 2 Diabetes
  Interventions:   Drug: Tirzepatide;   Drug: Semaglutide
  Sponsor:   Eli Lilly and Company
  Recruiting
• Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD

  NCT03937479

  Condition:   COPD
  Interventions:   Drug: Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium;   Drug: Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium;   Drug: Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium;   Drug: Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium;   Drug: Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium
  Sponsors:   Verona Pharma plc;   Iqvia Pty Ltd;   LGC Limited
  Recruiting
• A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

  NCT03931785

  Condition:   Irritable Bowel Syndrome With Diarrhea (IBS-D)
  Interventions:   Drug: MD-7246;   Drug: Placebo
  Sponsors:   Ironwood Pharmaceuticals, Inc.;   Allergan Sales, LLC
  Recruiting
• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  NCT03915964

  Condition:   Rheumatoid Arthritis
  Interventions:   Drug: Baricitinib;   Drug: TNF Inhibitor
  Sponsors:   Eli Lilly and Company;   Incyte Corporation
  Recruiting
• Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis

  NCT03890120

  Condition:   Primary Sclerosing Cholangitis
  Interventions:   Drug: Cilofexor;   Drug: Placebo
  Sponsor:   Gilead Sciences
  Recruiting
• A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

  NCT03730662

  Condition:   Type 2 Diabetes Mellitus
  Interventions:   Drug: Tirzepatide;   Drug: Insulin Glargine
  Sponsor:   Eli Lilly and Company
  Recruiting
• Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms

  NCT03569007

  Condition:   Celiac Disease
  Interventions:   Drug: Larazotide;   Drug: Matching Placebo
  Sponsor:   Innovate Biopharmaceuticals
  Recruiting
• A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092

  Condition:   Ulcerative Colitis
  Interventions:   Drug: Mirikizumab;   Drug: Placebo
  Sponsor:   Eli Lilly and Company
  Recruiting
• An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086

  Condition:   Ulcerative Colitis
  Interventions:   Drug: Mirikizumab;   Drug: Placebo
  Sponsor:   Eli Lilly and Company
  Recruiting
• A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

  NCT03518034

  Conditions:   Hypogonadism;   Cardiovascular Diseases
  Interventions:   Drug: Testosterone;   Drug: Placebo
  Sponsors:   AbbVie;   Acerus Pharmaceuticals Corporation;   Allergan Sales, LLC;   Endo Pharmaceuticals;   Upsher-Smith Laboratories
  Recruiting
• QP ExCELs: MultiPole Pacing (MPP) Sub-Study

  NCT03155724

  Condition:   Heart Failure
  Intervention:   Device: MultiPole Pacing
  Sponsor:   Biotronik, Inc.
  Recruiting
• Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP

  NCT02923726

  Condition:   Sudden Cardiac Death
  Interventions:   Device: Arm 1 (ATP+Shock);   Device: Arm 2 (shock only)
  Sponsors:   Boston Scientific Corporation;   ICON plc
  Recruiting
• Triple Combination Therapy in High Risk Crohn's Disease (CD)

  NCT02764762

  Condition:   Crohn Disease
  Interventions:   Drug: Vedolizumab;   Drug: Adalimumab;   Drug: Methotrexate
  Sponsor:   Takeda
  Recruiting
• Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads

  NCT02290028

  Condition:   Heart Failure
  Intervention:   Device: Sentus QP left ventricular lead
  Sponsors:   Biotronik SE & Co. KG;   Biotronik, Inc.
  Recruiting
• Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

  NCT01872975

  Conditions:   Stage IB Breast Cancer;   Stage II Breast Cancer
  Interventions:   Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
  Sponsors:   NSABP Foundation Inc;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
  Recruiting
• An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

  NCT03950232

  Condition:   Ulcerative Colitis
  Intervention:   Drug: Etrasimod
  Sponsor:   Arena Pharmaceuticals
  Recruiting
• Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

  NCT03945188

  Condition:   Ulcerative Colitis
  Interventions:   Drug: Etrasimod;   Drug: Placebo
  Sponsor:   Arena Pharmaceuticals
  Recruiting
• Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

  NCT03893448

  Conditions:   Pneumococcal Infections;   Pneumococcal Vaccines
  Interventions:   Biological: V114;   Biological: Prevnar 13™;   Biological: RotaTeq™;   Biological: Pentacel™;   Biological: RECOMBIVAX HB™;   Biological: VAQTA™;   Biological: M-M-R™;   Biological: VARIVAX™;   Biological: HIBERIX™
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

  NCT03769090

  Condition:   Asthma
  Interventions:   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg;   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg;   Combination Product: Albuterol sulfate metered-dose inhaler 180 μg
  Sponsor:   Bond Avillion 2 Development LP
  Recruiting